Willem Lesterhuis

Dr

  • The University of Western Australia (M503), 35 Stirling Highway,

    6009 Crawley

    Australia

  • 1489 Citations
  • 19 h-Index
20082021
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Willem (Joost) Lesterhuis is an NHMRC RD Wright Research Fellow with the National Centre for Asbestos Related Diseases (NCARD) at the University of Western Australia in Perth.

Joost completed his clinical training as a medical oncologist at the Radboud University Nijmegen Medical Centre in the Netherlands, while combining it with a PhD in tumour immunology. He moved to Perth for two years, working as a visiting post-doc at the Tumour Immunology Group at the University of Western Australia, after which he worked as a medical oncologist/cancer scientist at the Academic Medical Centre at the University of Amsterdam in the Netherlands.

Since 2013 Joost works as a full time scientist at the School of Medicine and Pharmacology/National Centre for Asbestos Related Diseases at the University of Western Australia.

Research

Current research projects include:
1- Combining chemotherapy and immunotherapy to treat cancer, in particular mesothelioma and lung cancer.
2- Unravelling the cellular and molecular processes that govern successful immunotherapy-induced cancer regression, using systems biology approaches.
3- Identification of the molecular processes that drive mesothelioma invasion using network analysis of high-dimensional molecular data from mouse models and patient samples.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 21 Similar Profiles
Neoplasms Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Mesothelioma Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Cross-Priming Medicine & Life Sciences
Vaccination Medicine & Life Sciences
Dendritic Cells Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2021

Research Output 2008 2017

  • 1489 Citations
  • 19 h-Index
  • 29 Article
  • 7 Review article
  • 4 Letter
  • 1 Chapter (peer-reviewed)

A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice

Aston, W. J., Hope, D. E., Nowak, A. K., Robinson, B. W., Lake, R. A. & Lesterhuis, W. J. 16 Oct 2017 In : BMC Cancer. 17, 1, 684

Research output: Contribution to journalArticle

Open Access
Maximum Tolerated Dose
Drug Therapy
Inbred C57BL Mouse
Dexamethasone
Weight Loss
2 Citations

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity

Hato, S. V., Figdor, C. G., Takahashi, S., Pen, A. E., Halilovic, A., Bol, K. F., Vasaturo, A., Inoue, Y., Haas, N. D., Verweij, D., Van Herpen, C. M. L., Kaanders, J. H., van Krieken, J. H. J. M., Van Laarhoven, H. W. M., Hooijer, G. K. J., Punt, C. J. A., Asai, A., de Vries, I. J. M. & Lesterhuis, W. J. 1 Jan 2017 In : Oncotarget. 8, 33, p. 54434-54443 10 p.

Research output: Contribution to journalArticle

Open Access
File
STAT Transcription Factors
Platinum
Transducers
Cisplatin
Pharmaceutical Preparations
21 Citations
Open Access
File
Tumor Biomarkers
Biomarkers
Mathematics
Drug Industry
Therapeutics
2 Citations

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition

Ebbing, E. A., Steins, A., Fessler, E., Stathi, P., Lesterhuis, W. J., Krishnadath, K. K., Vermeulen, L., Medema, J. P., Bijlsma, M. F. & van Laarhoven, H. W. M. 1 Jul 2017 In : Gastroenterology. 153, 1, p. 63-76.e14

Research output: Contribution to journalArticle

TYK2 Kinase
Epithelial-Mesenchymal Transition
Heterografts
Transforming Growth Factor beta
Adenocarcinoma
4 Citations

Transient Treg depletion enhances therapeutic anti-cancer vaccination

Fisher, S., Aston, W., Chee, H. E. J., Khong, A., Cleaver, A., Solin, J., Ma, S., Lesterhuis, W., Dick, I., Holt, R., Creaney, J., Boon, L., Robinson, B. & Lake, R. Mar 2017 In : Immunity Inflammation and Disease.. 5, 1, p. 16-28 12 p., 10.1002/iid3.136

Research output: Contribution to journalArticle

Open Access
File
Vaccination
Neoplasms
Diphtheria Toxin
Therapeutics
Immunity